At the time of writing, Sana Biotechnology Inc [SANA] stock is trading at $9.94, up 17.63%. An important factor to consider is whether the stock is rising or falling in short-term value. The SANA shares have gain 22.11% over the last week, with a monthly amount glided 81.72%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 13, February 2024, Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP. In a post published today on Yahoo Finance, Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration.
From an analyst’s perspective:
Sana Biotechnology Inc [NASDAQ: SANA] stock has seen the most recent analyst activity on January 16, 2024, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $12 for it. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 25, 2023, and set its price target to $9. On September 05, 2023, Citigroup initiated with a Buy rating and assigned a price target of $8 on the stock. TD Cowen started tracking the stock assigning a Market Perform rating. H.C. Wainwright initiated its recommendation with a Neutral. Morgan Stanley started tracking with a Overweight rating for this stock on March 01, 2021, and assigned it a price target of $40. In a note dated March 01, 2021, JP Morgan initiated an Neutral rating and provided a target price of $35 on this stock.
For the past year, the stock price of Sana Biotechnology Inc fluctuated between $2.74 and $9.15. Sana Biotechnology Inc [NASDAQ: SANA] shares were valued at $9.94 at the most recent close of the market.
Analyzing the SANA fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.95 points at the first support level, and at 7.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.46, and for the 2nd resistance point, it is at 10.99.
Sana Biotechnology Inc [SANA] reported earnings per share of $0.02 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.45/share, meaning a difference of $0.47 and a surprise factor of 104.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.59 per share as compared to estimates of -$0.43 per share, a difference of -$0.16 representing a surprise of -37.20%.
Ratios To Look Out For
It is important to note that Sana Biotechnology Inc [NASDAQ:SANA] has a current ratio of 4.19. On the other hand, the Quick Ratio is 4.19, and the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved NELSEN ROBERT, Director, that happened on Feb 08 when 1.82 million shares were purchased. 10% Owner, CRANDELL KEITH completed a deal on Feb 08 to buy 1.82 million shares. Meanwhile, 10% Owner ARCH Venture Fund X, L.P. bought 1.82 million shares on Feb 08.
